To resolve a spate of whistleblower lawsuits, drug manufacturer Cephalon Inc. of Frazer, Pa., has agreed to pay $431 million in civil and criminal fines for illegally promoting “off-label” uses for three of its drugs, federal prosecutors said.
In a global settlement with the U.S. Justice Department, Cephalon agreed to pay $375 million to settle False Claims Act claims by the Medicaid and Medicare trust funds and to plead guilty to a single misdemeanor criminal charge of distribution of misbranded drugs and pay $50 million in fines and forfeiture.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
